Sangamo Announces AAV Capsid Data

Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results

Conference Call and Webcast Scheduled for 9:15 a.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 4, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights.